விழித்திரை டிஸ்ட்ரோபி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from விழித்திரை டிஸ்ட்ரோபி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In விழித்திரை டிஸ்ட்ரோபி Today - Breaking & Trending Today

Investegate |MeiraGTx Announcements | MeiraGTx: MeiraGTx Reports First Quarter 2021 Financial and Operational Results

MeiraGTx Reports First Quarter 2021 Financial and Operational Results
LONDON and NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the first quarter ended March 31, 2021 and provided an update on recent progress.
“During the first quarter of 2021, we continued to advance our clinical and preclinical programs, as well as our proprietary cGMP manufacturing process. We are progressing rapidly with our riboswitch gene regulation technology platform and we are excited to share
in-vivo data later this year,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx. “This will be an important year for MeiraGTx as the Company prepares for the initiation of two Phase 3 pivotal trials in X-linked retinitis pigmentosa and ....

City Of , United Kingdom , Ben Rickles , Meiragtx Holdings , Janssen Pharmaceuticals Inc , Drug Administration , Janssen Pharmaceutical Companies Of Johnson , Clinical Development , Reports First Quarter , Alexandria Forbes , Janssen Pharmaceuticals , Janssen Pharmaceutical Companies , X Linked Retinitis Pigmentosa , Retinal Dystrophy , Induced Xerostomia , Investigational New Drug , Gene Regulation Platform , Fast Track , Supply Chain , Private Securities Litigation Reform Act , Quarterly Report , Three Month Periods , Ended March , நகரம் ஆஃப் , ஒன்றுபட்டது கிஂக்டம் , ஜான்சன் மருந்துகள் இன்க் ,

MeiraGTx Reports First Quarter 2021 Financial and Operational Results

MeiraGTx Reports First Quarter 2021 Financial and Operational Results
LONDON and NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the first quarter ended March 31, 2021 and provided an update on recent progress.
During the first quarter of 2021, we continued to advance our clinical and preclinical programs, as well as our proprietary cGMP manufacturing process. We are progressing rapidly with our riboswitch gene regulation technology platform and we are excited to share
in-vivo data later this year, said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx. This will be an important year for MeiraGTx as the Company prepares for the initiation of two Phase 3 pivotal trials in X-linked retinitis pigmentosa and ....

City Of , United Kingdom , Ben Rickles , Meiragtx Holdings , Janssen Pharmaceuticals Inc , Drug Administration , Janssen Pharmaceutical Companies Of Johnson , Clinical Development , Alexandria Forbes , Janssen Pharmaceuticals , Janssen Pharmaceutical Companies , X Linked Retinitis Pigmentosa , Retinal Dystrophy , Induced Xerostomia , Investigational New Drug , Gene Regulation Platform , Fast Track , Supply Chain , Private Securities Litigation Reform Act , Quarterly Report , Three Month Periods Ended March , நகரம் ஆஃப் , ஒன்றுபட்டது கிஂக்டம் , ஜான்சன் மருந்துகள் இன்க் , ஜான்சன் மருந்து நிறுவனங்கள் ஆஃப் ஜான்சன் , மருத்துவ வளர்ச்சி ,

MeiraGTx Reports Fourth Quarter and Full Year 2020 Financial and Operational Results

MeiraGTx Reports Fourth Quarter and Full Year 2020 Financial and Operational Results
- Preparing to Initiate Phase 3 Lumeos Clinical Trial in AAV-RPGR
- Announced Positive Preliminary Clinical Data from AQUAx AAV-hAQP1 Phase 1 Trial for Treatment of Grade 2/3 Xerostomia
- Completed Build of Internal cGMP Plasmid and DNA Manufacturing Facility
- Strengthened Balance Sheet and Extended Cash Runway into Mid-2023
- First in-vivo Data from Riboswitch Gene Regulation Platform to be Presented in 2021
LONDON and NEW YORK, March 11, 2021 (GLOBE NEWSWIRE) MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial and operational results for the fourth quarter and full year ended December 31, 2020 and provided an update on recent progress. ....

United States , City Of , United Kingdom , Ben Rickles , Company Phase , National Institutes Of Health , Janssen Pharmaceuticals Inc , Drug Administration , Janssen Pharmaceutical Companies Of Johnson , American Academy Of Ophthalmology Annual Meeting , Corporate Development , Meiragtx Holdings , European Society Of Retina Specialists , Preclinical Development Teams , American Society Of Retina Specialists , Clinical Development , Initiate Phase , Clinical Trial , Positive Preliminary Clinical Data , Balance Sheet , Extended Cash Runway , Riboswitch Gene Regulation Platform , Alexandria Forbes , Fast Track , Janssen Pharmaceuticals , Janssen Pharmaceutical Companies ,